Abstract:Background: The incidence of primary liver cancer is increasing year by year. In 2022 alone, more than 900000 people were diagnosed with liver cancer worldwide, with hepatocellular carcinoma (HCC) accounting for 75%-85% of cases. HCC is the most common primary liver cancer. China has the highest incidence and mortality rate of HCC in the world, and it is one of the malignant tumors that seriously threaten the health of Chinese people. The onset of liver cancer is occult, the early cases lack typical clinical symptoms, and most of the patients are already in the middle and late stage when diagnosed. Therefore, it is very important to find new markers for the early detection and diagnosis of liver cancer, improve the therapeutic effect, and improve the prognosis of patients. Protein tyrosine phosphatase non-receptor 2 (PTPN2) has been shown to be associated with colorectal cancer, triple-negative breast cancer, non-small cell lung cancer, and prostate cancer, but its biological role and function in tumors remain to be further studied. Aim: To combine the results of relevant data obtained from The Cancer Genome Atlas (TCGA) to provide the first in-depth analysis of the biological role of PTPN2 in HCC. Methods: The expression of PTPN2 in HCC was first analyzed based on the TCGA database, and the findings were then verified by immunohistochemical staining, quantitative real-time polymerase chain reaction (qRT-PCR), and immunoblotting. The value of PTPN2 in predicting the survival of patients with HCC was assessed by analyzing the relationship between PTPN2 expression in HCC tissues and clinicopathological features. Finally, the potential of PTPN2 affecting immune escape of liver cancer was evaluated by tumor immune dysfunction and exclusion and immunohistochemical staining. Results: The results of immunohistochemical staining, qRT-PCR, and immunoblotting in combination with TCGA database analysis showed that PTPN2 was highly expressed and associated with a poor prognosis in HCC patients. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that PTPN2 was associated with various pathways, including cancer-related pathways, the Notch signaling pathway, and the MAPK signaling pathway. Gene Set Enrichment Analysis showed that PTPN2 was highly expressed in various immune-related pathways, such as the epithelial mesenchymal transition process. A risk model score based on PTPN2 showed that immune escape was significantly enhanced in the high-risk group compared with the low-risk group. Conclusion: This study investigated PTPN2 from multiple biological perspectives, revealing that PTPN2 can function as a biomarker of poor prognosis and mediate immune evasion in HCC.

Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis

Combined Phosphatase And Tensin Homolog (Pten) Loss And Fatty Acid Synthase (Fas) Overexpression Worsens The Prognosis Of Chinese Patients With Hepatocellular Carcinoma

Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.

Prognostic Value of Phosphotyrosine Phosphatases in Hepatocellular Carcinoma.

Decreased Expression of PTPN12 Correlates with Tumor Recurrence and Poor Survival of Patients with Hepatocellular Carcinoma.

Expression and Clinical Significance of TAp73α, P53, PCNA and Apoptosis in Hepatocellular Carcinoma

Phosphorylation of PED/PEA-15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma.

Associations of Components of PTEN/AKT/mTOR Pathway with Cancer Stem Cell Markers and Prognostic Value of These Biomarkers in Hepatocellular Carcinoma

The Effect of PPP2CA Expression on the Prognosis of Patients with Hepatocellular Carcinoma and Its Molecular Biological Characteristics

PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis

Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Expression of PTEN in hepatocellular carcinoma and its relationship with p53, cell proliferation and apoptosis

PTEN-protein Expression in Hepatocellular Carcinoma and Its Association with Invasion and Metastasis

EXPRESSION OF PTEN GENE IN HUMAN HEPATOCELLULAR CARCINOMA AND ITS CLINICAL SIGNIFICANCE

The Expression of Tumor Suppressor Gene PTEN in Hepatocellular Carcinoma

Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma

Epigenetic and Genetic Alterations of PTEN in Hepatocellular Carcinoma

Expressions of Phosphorylated-Smad2 and PTEN in Hepatocellular Carcinomas and Adjacent Liver Tissues

Potential Role and Clinical Value of PPP2CA in Hepatocellular Carcinoma.

Effect of stability of PTEN on hepatocellular carcinoma

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.